TorreyPines Therapeutics Initiates Second Phase I Clinical Trial Of NGX426, A Potential Novel Oral Treatment For Chronic Pain Conditions

Tue, 27 Feb 2007 02:00 PM EST

... TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that it has initiated a second Phase I clinical trial of NGX426, a novel product candidate intended to treat chronic pain conditions such as migraine and neuropathic pain. NGX426 is an oral prodrug of tezampanel, the company's parenteral product candidate currently in a Phase IIb clinical trial for acute migraine. [click link for full article] ...